Biogen Raises 2026 Adjusted EPS Floor by 20 Cents
Biogen raised the lower end of its 2026 adjusted EPS guidance by 20 cents. Rare-disease revenue increased 27%.
Story updates
02:32:11 PM UTC
SquawkNews
更新版 1-百健凭借罕见病药物的强劲表现，季度业绩超出市场预期 将2026年调整后每股收益的下限上调20美分 罕见病药物销售额增长27%，达到6.76亿美元 预计到2027年底，Apellis交易将带